Emergent Biosolutions Inc. (NYSE:EBS) hit a new 52-week low on Wednesday . The company traded as low as $26.14 and last traded at $26.28, with a volume of 121,711 shares trading hands. The stock had previously closed at $27.06.

A number of equities research analysts have weighed in on EBS shares. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Cowen and Company reiterated a “hold” rating and set a $33.00 price target on shares of Emergent Biosolutions in a research report on Sunday, August 7th. JPMorgan Chase & Co. dropped their price target on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research report on Friday, August 5th. Wells Fargo & Co. reissued a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Finally, Singular Research lowered their price objective on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, June 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.00.

The stock has a market capitalization of $1.07 billion and a P/E ratio of 18.8651. The stock has a 50-day moving average price of $29.76 and a 200 day moving average price of $35.33.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.01. The business had revenue of $101.49 million for the quarter, compared to the consensus estimate of $111.20 million. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.36 EPS. Analysts forecast that Emergent Biosolutions Inc. will post $1.03 EPS for the current fiscal year.

In other Emergent Biosolutions news, Director George A. Joulwan sold 4,700 shares of the company’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $44.12, for a total value of $207,364.00. Following the transaction, the director now directly owns 20,785 shares in the company, valued at approximately $917,034.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.